# Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis

> **NCT06906549** · PHASE4 · RECRUITING · sponsor: **University Hospital, Strasbourg, France** · enrollment: 260 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Rituximab (RTx)

## Interventions

- **DRUG:** Rituximab 200mg/6months
- **DRUG:** Rituximab 1g/6months

## Key facts

- **NCT ID:** NCT06906549
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-11
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06906549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06906549, "Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06906549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*